Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the Elanco Animal Health Q4 2020 earnings conference call. At this time, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. Open to analysts only. Instructions will be given at that time for you to queue up for questions. If anyone has any difficulties hearing the conference, please press star followed by zero for an operator assistance at any time. Before turning the meeting over to management, please be advised that this conference call will contain statements that are forward-looking and subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. I would like to remind everyone that this conference call is being recorded, February 24, 2021. I will now turn the conference over to Tiffany Kanaga. Please go ahead, ma'am. Good morning. Thank you for joining us for Elanco Animal Health Q4 2020 earnings call. I'm Tiffany Kanaga, Head of Investor Relations. Joining me on today's call are Jeff Simmons, our President and Chief Executive Officer, Todd Young, our Chief Financial Officer, and Katy Grissom from Investor Relations. As always, during this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on slide two and those outlined in our latest Forms 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions. You can find our press release, the slides referenced on this call, and an investor workbook in the investor section of elanco.com. The slides and the press release also contain further information about the non-GAAP financial measures that we will discuss today during this call. After our prepared remarks, we will be happy to take your questions. I will now turn the call over to Jeff to provide the highlights. Thanks, Tiffany. Good morning, everyone. Before our results, a quick statement on the year. 2020 was a historic year for the world and for Elanco. As the COVID-19 pandemic shuttered businesses around the world, our Elanco essential workers in the labs and plants kept our pipeline and product flowing. Our sales and technical team shifted to serve customers in innovative ways for a virtual and curbside world, supporting the surge in telemedicine and doorstep delivery. Meanwhile, many of our functional experts doubled down on standing up Elanco systems, transitioning IT services from Lilly to our own, and delivering our industry's largest acquisition on time from their home offices. The Elanco team not only weathered the pandemic, keeping our customers at the center, but they transformed our company along the way. Listen, we started on our journey to create a purpose-driven company 15 years ago, and one of my biggest learnings from this past year, 2020, is that strong vision and purpose to make a difference create a level of loyalty and determination that I've never imagined. The Elanco executive team and I have deep gratitude for all that our team accomplished in 2020 and to our customers who made it all possible. Now to our results. Elanco enters 2021 with strong momentum. Our Q4 revenue of $1.14 billion surpassed the high end of our guidance by $70 million as U.S. Pet Health, U.S. Farm Animal, and China Swine outperformed our expectations. Our adjusted EPS of $0.12 came in at the high end of our guidance range. Our revenue overachievement and gross margin leverage were offset by what were largely one-time and targeted investments driving OpEx above our guidance. Our sales momentum and operational execution, as well as our pipeline launches year- to- date, are reflected in our increased full-year revenue, Adjusted EBITDA, and Adjusted EPS guidance. Let me provide the highlights from the Q4 before progressing to a more detailed review of our performance. Our Q4 revenue reflects market share gains in our U.S. Pet Health Retail business, ongoing improvement from COVID-19 headwinds in U.S. Farm Animal, and a better-than-expected performance in China Swine. Importantly, we achieved further share gains in the U.S. for many of our key pet health products compared to last year, including Credelio, Galliprant, Seresto, and the Advantage Family. Our buy-sell distributor strategy is working well and continues to improve our commercial competitiveness, with our channel inventory levels remaining consistent with prior quarters. At the same time, our strength in omnichannel capabilities provides unparalleled access to pet owners wherever they prefer to purchase, at the veterinarian, through specialty, and mass retail or e-commerce. We are raising our 2021 revenue guidance to reflect intact fundamentals and our focus on execution. For the year, we continue to forecast 3%-4% underlying revenue growth from innovation and portfolio contributions, building velocity as we move past the most challenging comparisons in the Q1. Increased revenue dollars are translating to higher-than-previously-expected Adjusted EBITDA and Adjusted EPS, as Todd will detail later. We are on track for eight innovation launches in 2021 and have already recorded our first sales for Credelio Plus in Japan and Increxxa in Europe, with approval received for Increxxa in the U.S. We continue to expect innovation to contribute $80million-$100 million in our 2021 revenue. Over time, innovation will deliver consistent, dependable revenue with a balance of blockbusters and complementary portfolio solutions. Our Q4 adjusted gross margin of 52.7% was driven by positive mixed benefit from U.S. Pet Health revenue outperformance, along with our continued progress on our M&Q productivity agenda. We achieved adjusted EBITDA of $176 million above the high end of guidance as well. However, our operating expenditures also exceeded guidance due to investments pressuring EPS by approximately $0.07. This outlay, which was largely one-time and discretionary in nature, backed important projects and our people. It can be divided into four categories that are roughly equal in size. First, brand building in the U.S. and China. Second, R&D acceleration and business partnering. Third, higher incentive comp from our sales outperformance, and fourth, legal and other IT infrastructure and stabilization-related costs. We come into 2021 with our senior leadership aligned and accountable for delivering on our OpEx guidance by realizing synergies, executing with discipline, and making the necessary trade-offs to keep driving growth. We continue to make progress in integrating Bayer Animal Health and driving our operational efficiencies. Our January 26 restructuring announcement marked the next wave of value- capture actions. With this and our September actions, our headcount reductions are expected to drive approximately half of our total synergies. We believe that our savings and procurement and the rationalization of smaller and/or overlapping R&D projects will deliver $40 million-$50 million of our synergies in 2021. In total, we expect $160 million-$175 million of cumulative synergies to be achieved in 2021, well on the way to the anticipated $300 million outlined by the end of 2023. At our December 15 investor day, we provided a detailed explanation of how our innovation portfolio and productivity strategy, or IPP, will underpin our long-term growth algorithm that we believe will drive 3%-4% average annual revenue growth, double-digit annual adjusted EBITDA growth, and double-digit annual adjusted EPS growth. Our updated 2021 guidance today is balanced, demonstrating positive momentum in our underlying business that is in line with this algorithm. On slides three and four, let me summarize our execution in the Q4. On the top line, Legacy Elanco delivered $743 million, while Bayer contributed $396 million, with each ahead of our expectations. In Pet Health, our focus brand Credelio, which has now achieved blockbuster status, posted double-digit growth and U.S. market share gains year- over- year. We're also seeing further traction in the pairing opportunity with Interceptor Plus. Used together, these products provide pet owners with the broadest flea tick and worm coverage in the market today. The increase in pairing also reflects the benefits of our partnership efforts, including our dog park study last year with IDEXX, showing that one in five dogs visiting dog parks in major U.S. cities tested positive for intestinal parasites. Kynetec dispensing data for the Q4 shows that when Interceptor Plus is sold with a flea and tick solution, it's paired with Credelio over 50% of the time, sequentially improving from September and up double digits year- over- year. Meanwhile, we're actively optimizing the profitability of our defend brand Trifexis and applying omnichannel capabilities to grow its sales at retail during the quarter, partially offsetting its declines in the clinic. On the Bayer side, Seresto global revenue was $64 million in the Q4, up 13% year- over- year. Advantage Family global revenue was $100 million, up 5%, both at constant currency growth rates. In the U.S., Seresto and the Advantage Family both increased double digits, including approximately $10 million pulled into 2020 from 2021 from a large retail customer. The underlying growth for global Bayer of approximately 8% is an acceleration from the 4%-5% that we estimated in the earlier portion of the year, reflecting pandemic-related retail channel tailwinds amidst rising COVID case counts. For the full year, including the period before the acquisition, Seresto revenue was over $400 million, with constant currency total growth above 20%, and while the Advantage Family was closer to $500 million, up mid-single digits year- over- year. Turning to pet health therapeutics, Galliprant grew double digits in the Q4, reflecting our positioning strategy as a first-line treatment with a differentiated safety profile and its continued global expansion. In the U.S., Galliprant again outpaced the branded market in dollar growth compared to last year, according to the Kynetec data. Rounding out the category, pet health vaccines remained strong in the quarter in a favorable vet clinic backdrop. Looking at our farm animal business in the Q4, pressure from COVID on U.S. cattle and swine continued to lessen sequentially. Cattle on feed numbers are on par year- over- year, and processing backlog has largely dissipated. Elevated feed costs, with corn futures recently at seven-year highs, are pressuring producer economics but also improve our value proposition through performance products. Rumensin and Optaflexx sales exceeded our forecast in the quarter against an incrementally better industry backdrop, and we continue to navigate generic competition within our expectations. We also benefited from approximately $10 million in incremental U.S. cattle vaccine and implant revenue due to competitor stockouts. Outside the U.S., poultry and aqua remain negatively impacted by unfavorable macroeconomic conditions and reduced consumption, with trends largely unchanged from the Q4. International poultry challenges remain concentrated in mid-size emerging markets, including Central America, the Middle East, and India, more than offsetting growth in countries such as Brazil. In aqua, salmon prices were down nearly 40% year- over- year at quarter end, with reduced demand because of the pandemic. With salmon prices in some cases barely clearing production costs, we're seeing producers deterred from premium solutions like Clynav. We still expect pandemic and economic-related headwinds to negatively impact our international poultry and aqua businesses into mid-2021. However, both species remain important growth drivers for Elanco over time. Moving to China Swine, the business continued to see strong recovery compared to last year's African Swine Fever headwinds, contributing to outperformance versus guidance. Prices remained elevated for China Swine during the quarter due to tight supply and increased further in early January ahead of the Chinese New Year. Despite the recent release of frozen pork from state reserves, prices are still trending more than double the pre-ASF levels. In turn, we're seeing further investment in pig health and demand for our premium products. While ASF and other diseases remain problematic in China still today, our key customer base of large modernized farms have invested in biosecurity and are having the most success in rebuilding their herds. Moving to slide five, we continue to execute against our strengthened and expanded IPP strategy. Let me touch on a few of the key points, starting with innovation. On slide six, we provided a status update for each of the eight launches planned this year. Let me now focus on three of those. The first is Credelio Plus in Japan in January. We are pleased with the initial reception, with strong launch sales as wholesalers and veterinary clinics stocked the product, but it remains very early days, still ahead of the season. Last week, we received a positive opinion from the European Medicines Agency, paving the way for a second quarter launch of Credelio Plus, our flea tick and worm combination product across the EU, and Australia remains on track for the Q3, in time for the parasiticide season in that geography. Next is Increxxa, a product for cattle and swine respiratory disease. Earlier this year, Increxxa launched in the competitive EU market. In the U.S., we've received approval for cattle and swine and expect to be in the first tranche of generic launches in the market. We continue to see Increxxa as a valuable complement to our existing farm animal respiratory care portfolio that will support our overall competitiveness. This will also include our data analytics and our performance evaluation services offered to Elanco Knowledge Solutions. And finally, we have Experior, which has indicated to reduce ammonia gas emissions from cattle. This is the first-of-its-kind product that provides feedlot managers with the freedom and flexibility to balance environmental stewardship and sustainability while delivering business results and animal performance beyond today's industry-leading technology. Experior has been adopted by the first full production and processing system, and we expect to have cattle on Experior by the end of the Q1. Additionally, last week, we received Canadian approval for Experior, the second-largest feedlot market, which will complement the U.S. launch. Looking at the total pipeline, we are advancing key development programs that we expect to deliver a consistent 2-3 percentage point contribution to average annual growth, representing a reliable driver of our long-term growth algorithm. Moving now to portfolio, the 14 Legacy Elanco products launched or acquired since 2015 grew 5% in 2020, excluding divestitures and despite COVID-related pressures. Details are included in the appendix on slide 22. Many of these recent innovations have transitioned into our focus brands, which will drive our sales growth in 2021 and years to come. We are a strategic global leader with a robust, diverse, durable portfolio, with more access to the world's animals than any point in Elanco's history. Our balance across brands, species, and geographies will allow us to maximize value and deliver on our sales growth expectations. Omnichannel is our sweet spot and one of our key growth enablers, and we're now the leader in retail and e-commerce, outpacing the double-digit industry growth in the U.S. market. Finally, on productivity, our manufacturing organization captured $115 million in cost savings and avoidance in 2020. Since 2018, the team has delivered $215 million in cost savings and avoidance, surpassing the expected $215 million and contributing most recently to our Q4 gross margin expansion and outperformance. We have transitioned all of our historic Elanco legal entities onto our new Elanco ERP system, with our new shared service centers in Poland and Malaysia executing our financial transactions. We've also moved all of our Legacy Elanco employees and facilities onto our own IT network infrastructure. As a result of this global effort, we plan to have exited all material Lilly TSAs on time and at the end of March. Let me summarize. Elanco is entering 2021 with strong momentum. Our Q4 results were at the high end or exceeded guidance on both the top and bottom line. We're gaining share in key pet health products, and our U.S. retail business was particularly strong in the Q4. U.S. Farm Animal is seeing sequential improvement, while China Swine is running ahead of expectations. Our innovation pipeline is on track to yield eight launches this year, with nine out of the 13 geographic approvals now received and only two without a final approval date confirmed. Our productivity agenda is intact, along with rapid action towards synergy capture. We are focused on execution in 2021 against the full-year guidance ranges that we have raised today. With that, I'll turn the call to Todd to provide more color on our results and outlook. Thanks, Jeff. Slide seven summarizes our financial results, including our reported net income and earnings per share. On slides 33 to 38 in the appendix, you can find a summary of the adjustments made to the reported results to arrive at our adjusted presentation. I'll focus my comments on our Q4 adjusted measures in order to provide insights on the underlying trends in our business, so please refer to today's earnings press release for a detailed description of the year-over-year changes in our Q4 and full-year reported results. Details on full-year results are also included in the appendix of our earnings slides. Looking at the adjusted measures on slide eight, you'll see the total Elanco revenue increased 45% in the Q4 on a reported basis. Foreign exchange impact was neutral. I'll break down the effect of Bayer on our revenue growth in a moment. On slide nine, there's a visual representation of our revenue performance versus the increased guidance range that we provided in mid-December. The key drivers of the better-than-anticipated results, in order of magnitude, were strength in our U.S. Pet Health retail business, improvement in U.S. Farm Animal, and the ongoing recovery in China swine. In Q4, gross margin as a percent of revenue was 52.7%, an increase of 480 basis points compared to the Q4 of last year. The improvement was driven by the inclusion of Bayer's higher margin business, positive price on Elanco's legacy portfolio, and continued productivity gains, partly offset by lower absorption driven by lower production volumes, fixed cost de-leverage, and negative product mix for Legacy Elanco. Total operating expense increased 92% in the Q4, including the addition of the Bayer animal health business. As a percent of sales, operating expenses increased from 32% in the year-ago period to 43% in this period and exceeded our guidance. As Jeff explained, this performance reflects the impact of four categories of expenditures that are roughly equal in size in terms of exceeding our expectations. First, brand-building investment has supported future revenue growth with a focus on supporting our good momentum in the U.S. Pet Health and China and enhancing our digital capabilities. Second, R&D acceleration with discretionary investment in key development projects and business development transactions, such as our December agreement with Kindred Bio to bring a first-of-its-kind canine parvovirus therapy to market. Third, higher incentive compensation as our sales performance outperformed the high end of our guidance by $70 million. And fourth, legal and other IT-related stand-up and stabilization costs. On slide ten, you will find a bridge depicting this walk between our expected and actual operating expenses. We would characterize this incremental operating investment as largely being either one-time or discretionary in nature. Operating income decreased 8%, improving from the 22% decline in the Q4, but still reflecting the elevated operating expenses that I just described. At the bottom line, Q4 adjusted net income decreased 35% to $56.7 million. The Q4 effective tax rate was 16.4%, reflecting a return to provision true-up. With our Adjusted EBITDA at $176 million, or $16 million above the high end of our guidance range from our revenue outperformance, our Adjusted EBITDA margin for Q4 was 15.4%. Now let's discuss our revenue performance more closely. On slide 12, you will see a breakdown of the contribution from Legacy Elanco and Legacy Bayer portfolios by category. Legacy Bayer products contributed $396 million of revenue in the Q4. On slide 13, you can see the effect of price, rate, and volume on our revenue performance. The benefit of the Bayer acquisition is reflected in volume. As is typical with acquisitions, we will continue to report the addition of the Bayer business in volume through Q4 of 2021 when we begin to lap the closing of the acquisition. For the Legacy Elanco business, price was up 6% for the Q4, demonstrating the value of our innovation and the ongoing discipline we are applying despite competitive pressures. Additionally, we experienced notable price benefits in pet health disease prevention from U.S. Pet Health vaccines as we continue to tighten our promotional practices. Slide thirteen provides a breakdown of our overall performance between the U.S. and our international operations. This Q4, we have further outlined our geographic performance by pet health and farm animal, as well as contract manufacturing, all of which benefited from the addition of Bayer. To assist with your modeling this Q4, we are providing additional reference slides with 2020 revenue on a combined company basis. Slide fourteen depicts this combined revenue by species, representing an update to our investor day disclosures, which were based on the midpoint of Q4 guidance and by major country. Please keep in mind that all estimates of combined revenues are materially correct. However, due to certain data limitations, including FX, these numbers may have some non-material differences to actuals. We are providing these combined numbers as a good faith summary to give better financial context to investors. As a reminder, going forward into 2021, we will report quarterly revenue by species. We intend to update revenue by country on an annual basis. We plan to file our 10-K shortly, but moving to slide fifteen, let me now offer a few words on working capital, cash, and our debt leverage. In the U.S., consistent with Q2 and Q3, we held all distributors at 60-day payment terms. In the Q4, day sales outstanding continued to improve sequentially, standing at 66 days versus the peak of 103 days in the Q1 of 2020. We ended the Q4 with $495 million in cash and equivalents on our balance sheet. With gross debt of $6.2 billion, our net debt is $5.7 billion. We continue to anticipate gross debt repayment of $500 million in 2021, with progress towards our net leverage goal of being below three times by the end of 2023. As a result of system cutovers related to our SAP implementation, we did draw $150 million on our revolver in early January to manage intra-company related liquidity. Now I will transition to our full-year and Q1 2021 outlook starting on slide seventeen. Today, we are updating our full-year 2021 guidance to reflect the good momentum entering the year by increasing the ranges for total revenue, adjusted EBITDA, and adjusted EPS. We now anticipate 2020 revenue of $4.55 billion-$4.63 billion, adjusted gross margin of 56%-57%, and OpEx of $1.73 billion-$1.75 billion, leading to adjusted EBITDA of $980 million-$1.04 billion. Our depreciation, interest expense, and tax rate assumptions are unchanged from mid-December. Within our Q4 2020 GAAP results, we were required to assign a valuation allowance against $75 million of our deferred tax assets from U.S. operations. Net, the flow-through from our higher revenue guidance is driving our increased adjusted EPS outlook of $0.90-$1 a share. We also continue to anticipate the same CapEx and net cash outlays as discussed at the investor day, while cash taxes are lower by $5 million. Slide eighteen offers a refreshed view of the bridge from our 2020 combined revenue to our raised 2021 guidance. Importantly, we continue to expect innovation and portfolio to provide a combined 3%-4% growth, despite ongoing headwinds from competitive pressures, generic interests, and macroeconomic challenges in international poultry and aqua. We are not providing 2020 pro forma line items for the combined company below revenue today, given the data limitations around that exercise. Moving to slide nineteen, we are providing guidance for the Q1 of 2021. We expect revenue of $1.15 billion-$1.17 billion and Adjusted EPS of $0.20-$0.25. Now I'll hand it back to Jeff. Thanks, Todd. Before moving to questions, we often like to share perspective on relevant industry trends that will become key in the years ahead. As we pivot into this next decade, we believe it's key to do that. Today, I'll touch on three trends that will make a meaningful impact, we believe, on our industry in the first half of this decade. The first being the changing pet care landscape. Second is climate policy, and third is innovation. These are areas where Elanco will continue to lead. First, the pet care landscape. More than two-thirds of pet owners say their dog is even more of an emotional companion than before the pandemic, changing our relationship with pets for the long term. This increased togetherness is translating into an increased expectation of care and driving growth in spending, clinic visits, and auto shipments. More specifically, on omnichannel presence. From the veterinarian to e-commerce, it's never mattered more. During COVID, about one-third of pet owners shifted their spending online, and nearly all expect to continue that. With about half of the world's 500 million pets still unmedicalized, our increasing access to pets creates an opportunity to be the bridge to drive increased pet care over the long term. The Bayer acquisition positions Elanco as the omnichannel leader. We will expand on this significant market trend as we head into this decade, with our growing portfolio of vet and OTC products, digital, omnichannel partnerships, and the next generation of value-creating innovation like connected care. The next trend to watch is climate policy. Cattle are often named as the leading culprit in greenhouse gas emissions, but healthy animals are actually a critical part of the solution, not the problem, the solution to sustainability. They upcycle the grass, forages, and food byproducts humans can't use. If we want to reduce greenhouse gas emissions from protein production, we must invest in farm animal innovation, where the ability to lower emissions dwarfs any impact of alternative proteins it could achieve. Elanco is committed to be the livestock producer's leading partner on the journey to net zero and our healthy purpose sustainability pledges. Today, animal agriculture is responsible for about 4% of U.S. greenhouse gas emissions. Elanco's portfolio already helps farmers and ranchers improve the sustainability of livestock production. For example, we reduced beef footprint by about 9%. We know livestock production can reach net zero by 2050. Many farms will do it this decade. Which leads me to my last point, innovation, the third trend. Innovation matters, and it's rewarded in this industry. As a global pet and livestock leader, Elanco is well positioned to source, develop, partner, fund, and globalize to create the next era of innovation and this flow in both pets and farm animals. As we close, let me review a few key points. Since closing the Bayer acquisition, our business is growing in line with or beyond our expectations, creating momentum and driving increased 2021 guidance. Our pipeline is progressing with nine of the 13 approvals needed to support our eight key 2021 launches. We're streamlining processes, optimizing our footprint, and delivering increased operational efficiency. Regarding the Elanco board, the increased engagement, governance, expertise in finance, innovation, and animal health, as well as having a shareholder perspective from our expanded and strengthened board, is bringing immediate value. With that, I'll turn it over to Tiffany to moderate the Q&A. Thanks, Jeff. We'd like to take questions from as many callers as possible. So we ask that you limit yourself to one question and one follow-up each. Christelle, please provide the instructions for the Q&A session, and then we'll take the first caller. At this time, if you would like to ask an audio question, please press star one on your touch-tone phones. Once again, that is star one to ask an audio question. Your first question comes from the line of Nathan Rich with Goldman Sachs. Good morning. Thanks for taking the question. Jeff, maybe starting with the pet health disease prevention. Price growth with 14%. You called out kind of tightening promotional practices. I guess, could you just maybe go into more detail on what changes were made and how sustainable this dynamic might be as we think about 2021? And then I think if I'm looking at the slides correctly, that would imply a sort of like 10% decline for the Legacy Elanco business. You talked about some of the key products seeing growth in volume and market share gains. So could you maybe just talk about what might have offset this? And then just quickly as a follow-up question for Todd, I don't think I saw any sort of EBITDA guidance for the first quarter. I think consensus is around $240 million. I'd just be curious if you could kind of give us some color on how you're thinking about first quarter EBITDA. Thank you. Nate, let me jump in first before we get to Jeff. I mean, we didn't give the EBITDA guidance, but we do feel good about the improving OPEX trend with the sequential decline relative to Q4. That $0.07 a share that Jeff talked about is a big driver of the improvement from $0.12 in Q4 up to the 20%-25%. $0.25 we've guided to in Q1, and with that, you would expect to see the EBITDA growth go from the $1.76 substantially higher as well, so while not giving specific guidance today, we do feel good about the continued EBITDA growth as shown by the raise of the full-year expectations for that. I would say, Nate, too, just on the price and the volume questions on pet health. I mean, first of all, there's no question our change in our distribution strategy is working. We're optimizing our partnerships. As you know, we've limited the number of partners that we have. We've moved a Claro product from Bayer over. When you just look at the overall underlying demand, what you're seeing here is demand is increasing. We're taking share. The gross to net and actually the efficiencies within the financial relationship has been a driver behind this. The price, as Todd mentioned in his comments, was really driven by strong demand, especially in vaccines. Duramune is resonating very well with vets right now from a brand perspective. And pet owners are paying more attention to their dogs. Wellness visits are up. All of this is driving and underpinning that. But I think the most important message is the tightness in our channel and our partnerships. It's working. We're optimized. And it's optimizing not just the financials and overall gross to net, which is helping price, but it's also helping us from a share of voice and competitiveness in the marketplace. The other thing to add, Nate, is with the divestitures we had last year, that's obviously negatively impacting our growth rate in the companion animal business. The other thing to note is we did lose sales in Trifexis, which is part of the decline we're seeing that is pulling down the overarching growth rate. We'll move to the next caller, please. Your next question from Erin Wright with Credit Suisse. Great. Thanks. Can you speak to some of the stocking, the stocking dynamics at the Bayer business and what you're wrapping here in the first half as it relates to that business? And can you quantify how much was pulled into 2020 from 2021 in terms of that purchase from a large retail customer and what sort of visibility or control you have on the inventory from a retail perspective? And then my second question is how we should think about the quarterly progression on the livestock business, particularly in the U.S. Can you break down some of the impact of the continuing COVID headwinds as well as wrapping some of those COVID headwinds? And then also we're mentioning competition. And then on top of that, new product launches. How do we think about those factors impacting that quarterly progression? Thanks. Aaron, let me tackle a couple of those. With respect to the retail, as we mentioned, there was a $10 million pull forward from one of our bigger players in that space that did get pulled in. Overall, as we've talked previously, there was an increase in total inventory at retailers driven by the growth in the dispensing action across 2020. A big pickup in retail and online OTC product growth. That That caused the retailers to continue to expand. We also saw more of our products being on the shelves in more retail locations, so all of that is a good news bit as there's a higher demand by customers for those products. With respect to the retail players versus our distribution network, we've got expectations from those retailers to deliver on time, full shipments when they make orders, and so they do control more of what they want to own on their shelves in that case versus our general negotiations and work with our distribution side on the vet side. Overall, we feel very good going into the parasiticide season with the levels of inventory that those retailers are holding as they are prepared for customers to continue to demand Seresto and Advantage Family as we go through the season. Erin, question on farm animals. So if you look at the market overall, our predictions are that the market as a whole will grow as a market around low-single-digit. We expect to outgrow that market, low-single- to mid-single-digit. Let me highlight kind of the list of things that will actually be the contributors to growth for us in farm animal because we do expect to increase our farm animal market share in 2021 globally. So the first is we have a COVID compare, as you know, as we came out of a tough year in our farm animal business with COVID. Two is we have performance products. And as you look at higher ingredient costs, as we've said, when you look at the futures on corn, it's $7. Our products actually, with our value-based customers actually and with our Elanco Knowledge Solutions, actually provide more value. So that's going to be a driver. Five of our eight new products are farm animal products, and they will contribute to our growth. I think the other note that we haven't mentioned is our Bayer Farm Animal portfolio. When you look at a Cydectin and a Baytril, adding and expanding to our portfolio in a significant way and adding to our access in the international markets. And then to your other question on generic Rumensin, we continue to differentiate in the field. We continue to work the portfolio, cattle and beef. It is meeting and in the fourth quarter exceeded our expectations. And then the last, of course, is China. China overall, especially pigs, but also poultry. As we've said, China will contribute to 1% of our total global growth in Elanco, and we're off to a very strong start. That's all offset by, again, the continued first half aqua and poultry and international. So again, farm animal business, I believe, differentiated in a good position, a new innovation, and planning to be low single- to mid-single-digit growth and take market share in 2021. As that ends on the COVID question, last Q1, we did have a pull forward in the international markets of about $20 million on the farm animal side in Q1 as just the concerns on disruption going into the COVID time. Offset in our U.S. pet business, where we did reduce the channel by $60 million as a result of COVID impact on our expectations of future demand. Offset with the Bayer business that grew on their pet health business 22% in the first quarter of 2020 versus 2019. So a number of different factors there. We know this creates greater clarity needs going into the year, and that's the reason we've provided the Q1 revenue guidance that we feel gives a good view of where we're headed here in Q1. Thanks. We'll take your next caller. Your next question comes from the line of Michael Ryskin with Bank of America. Hey, thanks for taking the questions. Congrats, Jeff, on the quarter. I want to go back to your comments on parasiticides a little bit. You had a lot of comments in the prepared remarks, and you sort of reiterated meaningful share gains in Credelio, Seresto Advantage. So I'm just wanting to go a little bit deeper on where the share gains are coming from, particularly in light of the triple combo launched by one of your competitors and the strong uptake in year one. So any details on whether it's in the vet or via the retail channel? Is it more driven by volume or price? Any particular category? Maybe you could comment on some of the legacy products, the older products besides the Credelio and the Seresto, things like that. And then follow-up question. You've now raised the 2021 outlook a few times in a relatively short amount of time since you initially provided it in mid-December. I'm just wondering if it's meant to signal a particular improvement in the markets, better execution on your part, or perhaps more that the initial outlook just had a little bit more room for upside. And do you feel like you still have enough room in the updated guide as you go through the year to potentially raise it further or just sort of where we are on that trajectory? Yes, Michael, thank you for the question. So parasiticides, I just always start from the broadest perspective, a $5 billion market with lots of dynamics. What I would share with you is that, as I mentioned, now is pet retail, OTC, and scripted products shipped to the door. That was why I highlighted that trend. We are outgrowing that market and taking share in double digit. That's one. Yes, that's led by Seresto and the Advantage Family, but other products as well. Second is Credelio. The Credelio performance continues to grow significantly. We continue to see if you're going to get full coverage to a pet today, you're going to need two products no matter what you want to use. And the two that are the most significant with the broadest coverage and being paired the most is Interceptor Plus and Credelio. So that combination and Credelio alone are also gaining share. And we'll continue to work with Seresto as we look at this globally. We would say also the pet business in China and some of the other aspects we talked about with the Bayer acquisition are also areas that contributed significantly in Q4. Offset by Trifexis. I will say Trifexis retail grew, and that is going to be a key factor for us, partially offsetting the declines that Todd mentioned in the vet clinics with Trifexis. So we feel very good about that. Then as we enter this year, the $1.5 billion market of the market I just mentioned is OUS. We now can match any portfolio today or even surpass it in the international markets with Credelio Plus. And then, as Aaron highlighted, 11 candidates in our pipeline, one a year that we will continue to innovate aggressively into this big marketplace. So well-positioned, those are the drivers in Q4. Michael, with respect to your question on guidance, the first update in January was related to restructuring. Those are something that we work very hard to get right. It's always tough to impact team members that have been delivering for us, but it was necessary to continue to drive operational efficiencies. And once our board approved it, we reflected that in updating our guidance from the savings that comes from that. The update today is continued execution. It's in December 15th on our investor day with the preparation for that happening from mid-November on. And our new commercial leadership really getting the complete portfolios underneath their feet and really understanding the business. We are now two-plus months later in a much better position to see the value they're driving, the commercial execution our sales teams are doing, the impact that global marketing is having and driving underlying demand. And with that, we're pleased to be able to increase the top line as well as EPS guidance for the full year today. So again, overall, we feel the balanced and good understanding of our business. The innovation portfolio is getting launched as we talk, but the acceleration of that from a top line impact is really back half of the year. We'll move to the next caller, please. Your next question comes from the line of Balaji Prasad with Barclays. Hi, good morning and congratulations on the results. Appreciate the very comprehensive color in the earnings deck. A couple of questions from me. Firstly, on the parasiticides market, following up on what you discussed earlier, can you help us quantify what a broad flea-tick heartworm coverage means in terms of portion of the market where you get exclusive access to with limited competition or if it's even the right way to look at it? Secondly, Credelio blockbuster, can you clarify if it is Credelio only or if it's a function of Credelio and Credelio Plus? And on China swine, can you help us understand the pace of recovery that we need to factor in during the course of the year? And also, there have been recent developments of news flows of ASF recurrence as a function of illegal vaccines. A concerning factor is that this seems to be the fourth largest commercial producer in China. So any update on that would be great. Thanks. Lastly, 2021 guidance, key swing factors that you see looking out from here. Thank you. Yes, thank you for the question. So I'll handle the first one that's, I think, pretty straightforward. Credelio, we know over $100 million is a blockbuster. It was Credelio alone. Credelio Plus did not really enter the market in Japan until January. So that's straightforward. And then look, as we know and we've talked about, as you think through worm coverage and think about heartworm, roundworm, hook, whip, lung, and tape, all of those are the factors of coverage. So when we look at the series of those worms and the intestinal worms especially, and what we saw with the IDEXX study is that the prevalence is there. It's not something you want to take a risk with. A flea and a tick product, this is why the pairing study with IDEXX and our initiatives and campaign have become very key. We'll continue to play that out. I will also just speak that Credelio Plus is a product we're not bringing to the U.S., given that there's different regulatory constraints on heartworm. So that's how we see this market. Again, a little shy of about a $5 billion market, a billion and a half internationally. And again, the split between the retail channel and the vet channel. And then, yeah, China swine, yes, there are, you're exactly right. There are continued cases of African swine fever in China. We have not surpassed that. That pandemic continues. What though has happened, very clearly, we're seeing the new cases primarily in backyard herds that are still very common and still a high percentage of pigs in China. What has happened, though, is the shift in where our business comes is from the industrialized larger companies that have really advanced their biosecurity and are advancing actually their share of the marketplace. And that's where our business primarily is. Apologies, was there a question on guidance? Can you follow up? Can you remind us of this? Yes. On guidance, I was asking what are the key swing factors for your 2021 guidance considering the variation we saw in Q4 where guidance was as actual? And also on China, I had a follow-up because the outbreak was in the fourth largest commercial producer in China and not just backyard. So I wanted to see if you had any take on that. Thanks, Jeff. Let me add that and then Todd can end on guidance. Yeah, there were some limited cases. Again, the supply chains for some of the larger producers continue to be fragmented. But what I would say is what's most important here is the actual processing supply chain and the picking up of the pigs and the processing. That's where the disease spreads. So you're going to have certain cases. But as we assess it and we spend a lot of time on this, we believe that, again, our business is sound. We still hold to our guidance overall with our China assumptions of it contributing up to 1% of our total growth. And we'll continue to monitor this and update you as we go forward. With respect to the guidance, I think the three big swing factors, first would be the innovation launches. While confident in that, anytime you're launching new products and changing customer behavior, it requires a big effort. And we feel good, but it is something we need to execute against. Second would be the season for flea and tick. Now, with a much bigger over-the-counter product base, the weather and the seasonality of flea and tick is a bigger impact than on the vet business with orals. And so that's one we're paying very close attention to. And finally, the COVID impact. It has pluses and minuses as we've talked about in this past year with the over-the-counter and the retail operations, but then also the food service impact on our farm animal business, especially with the salmon and international poultry. Thank you. Next caller. Thanks. Your next question comes from the line of David Risinger with Morgan Stanley. Hi, this is Melina Santoro on for Dave. Could you please discuss your 2021 pipeline revenue contribution in more detail, maybe in particular the cadence of sales ramp over the course of the year, and then also the outlook for these products beyond 2021? Thank you. Yeah, as we've talked, we expect these to be $80 million-$100 million in total. They're going to be generally back half loaded as we're launching a lot of them here late in Q1/early into Q2, so the natural ramp that would come with the timing. And then over time, we expect certain of the products to grow more, certain of them to have a pretty substantial amount of expected growth here in the first year. But overall, we've talked that innovation will be the 2%-3% annual growth contributor for us as we go forward. We'll take the next caller. Thanks. Your next question comes from the line of Umer Raffat with Evercore ISI. Hi, thanks so much for taking my questions. I had two, if I may. First, back in December, you showed a revenue bridge from 2020 to 2021, which mentioned a Bayer retail stock-in of $25 million. And I saw a similar revenue bridge today, but the amount for that Bayer retail stock-in is now $45 million, not $25 million. Can you explain to us exactly what that is and what led to that change? Because that number was for 2020, and you kind of gave that number in mid-2020. So I'm trying to understand if something changed in the last couple of weeks of December. Separately, and I should have asked this back at the. When Bayer acquisition was announced, you had mentioned the target of reaching less than three times net leverage by 2022. I know you changed that to 2023 as of the analyst day. Our sense is it's the obvious; it's the inventory plus COVID. But if there's any other meaningful driver, I would love to hear from you. Thank you very much. Sure, Umer. On the question regarding the retail, to correct that it did go from $ 25 million- $ 45 million, two things in play there. One, the outperformance we had from underlying demand and dispensing. That we discussed earlier in the call regarding a big retail buyer as part of negotiations going into 2021. So all good news that there's a continued underlying demand for these OTC products and that we're getting on to more shelves in more locations across the U.S. And then with respect to the net leverage, yes, as we know, we've underperformed in 2020 relative to what our expectations were at the time we announced the Bayer transaction in August of 2019. The result of that is it's going to take us longer to be able to pay down our debt and deliver on that three-time net leverage. It's now 2023. Thank you. We'll take the next caller, please. Your next question comes from the line of Elliot Wilbur with Raymond James. Thanks. Good morning. Just a quick upfront question for Todd with respect to operating cash flow metrics. Could you just provide what cash flow from operations was in the quarter? And given the ongoing restructuring program, how is that going to impact operating cash flow over the course of 2021? Just any color you could provide on cash conversion metrics would be helpful. And then, for Jeff, just going back to your commentary early in the Q&A regarding the positive price impact on the U.S. health business. I just want to make sure I understand your commentary. So that is primarily a reflection of favorable changes in GTN trends given the change in distribution strategy, not reflective of actual list price increases. But if that's so, how would that look over the course of the year as you begin to lap those changes? Is it still a favorable impact in Q2, sort of an outsized one, and then just becomes a neutral, or you revert back to sort of low positive increments? Or could it actually become more of a negative dynamic in the second part of the year? Thanks. Yeah, let me take the first one. Thank you for the question, Elliot. So yeah, as we said, the couple of dynamics were in the pet health preventative segment driven by vaccines, driven by Duramune. That was one of the big factors here on price. And then also the compare to a year ago. So those are factors in here. But yes, the distribution change and the ability to get price there has been a big factor and just creating efficiency by giving away less and being able to create more demand with a bigger team, bigger portfolio, and have targeted distributors doing what they're best at. That we knew would be a factor in this positively, and it has been. As you look going forward, and we pressure test this a lot, we continue to hold to our guidance of a 2% price over the long term on our total portfolio. Elliot, thanks for the question on cash flow. We lost about $90 million in operating cash flow in Q4. As you noted, we've got a lot of the ongoing challenges with our restructurings and the costs it's taking from that. As we look forward into 2021, we've called out that we'll pay down $500 million of gross debt from the EBITDA we're going to generate. That will require an improvement in working capital and some other items given the calls on cash are going to soak up a large portion of that or about all but $150 million. So this is going to continue to be a reasonably large cash year. As we've mentioned, let me just call out the big items. There's $250 million for the restructuring and other one-off items. There's about $150 million in normal CapEx. You've got about $225 million in cash interest, and then the improvement of $5 million to about $25 million-$30 million in cash taxes. So with that, we feel confident in our ability to pay down the $500 million of gross debt. And we've got programs already initiated to improve the amount of inventory we're holding on our balance sheet to do that. Thanks. We'll take a few more callers. Next caller, please. Your next question comes from the line of David Westenberg with Guggenheim. Hi, this is John. I'm for Dave. Thanks for taking my questions. Firstly, how should we think about veterinary margins in terms of economic reopenings and a back-to-work environment? And my second question, if there's time, is do you think that there might be any one-time benefits in any product areas? Like, for example, you have a strong anti-anxiety franchise with Clomicalm. Could that do well? And are there any other areas that could benefit? Thank you. Yeah, great questions. The vet clinic market has risen with the tide of COVID and has benefited from this. I also believe the vet clinic market and veterinarians around the world have moved in a transformative way faster than they normally would have, from curbside service to telemedicine to participating in the retail and omnichannel. Starts and ends, we believe our industry with a veterinarian, one of the key things that we will do is partner with a veterinarian and bring them into this omnichannel and this pet owner that wants to shop in different places. So as I look at the vet clinic, there's no question we continue to see some consolidation with corporates. But we also see the other segment, more value add, more transformation, looking at revenue from multiple streams and becoming a lot more virtual and playing into the omnichannel. That, I would say, is not just in the U.S., but we're seeing that as well globally. We don't really see any, I think to Todd's point, if we look at product segments, new products, three on the pet side, five on the farm animal side, all are going to add significant value, whether it's raised without antibiotics and poultry, and that trend to Experior and link to sustainability net zero to Credelio Plus, broad spectrum differentiation packaged into our portfolio internationally. These are all key markets that actually can play. But otherwise, the environment linked to our business, the only other one I would point to is we do have a performance-driven farm animal portfolio, and that plays well as feed costs go up. Our value, if measured and it's a value-based customer, goes up as well. So that would be another one I would note. But primarily, it's new products and the adoption and the building of our new products. All right. We'll move to the next caller. Your next question comes from the line of Kathy Miner with Cowen and Company. Thank you for taking my question. Just two short ones. First, just a clarification, please. When you talked about your outlook for the farm animal to grow low single digit as a market, does that assume that all species grow within that, or will some be more pressured? And is that also true for Elanco? Second question is on business partnering. You commented that the parvovirus was one of them in this quarter. Were there any others? And should we anticipate more of these going forward? And are those in your guidance? Thank you. Great questions, Kathy. Yes, so farm animal, as we look forward, we would say that as you look at species, I think as a whole, globally, poultry has probably got the most challenge coming into the year with continued some disruption, as we've talked about, some economic challenge in some of the mid-size markets that we see as important in poultry, but still expected to be, as you look at the market, 1%-2% growth across all regions in aggregate. As you look at swine, we are cautiously optimistic around global swine markets in 2021. Production expected to grow around 6%, driven by China, as we just mentioned, but also some nice balance and really less of a COVID compare on the U.S. side and some of the other markets as well. China and U.S. keeping swine up. Beef, maybe the most optimistic we've seen in a while. Placements and marketings are expected to be ahead of 2020 levels as the industry fully stabilizes, and we'll continue to watch that. Dairy continues to have its challenges, but again, less material to us. The market growing as an industry, low single digit. Our goal is to outgrow that market and take market share. Business partnering, yes. We had the Kindred deal. We don't disclose all deals relative to our pipeline, but as Aaron highlighted on Investor Day, inside his P&L, he will continue to have acquisition dollars within his R&D budget to continue to partner, to acquire, to share technology platforms. As they come further into development, we'll be including them and adding them to our 45-plus candidates to become our 25 launch equivalents, Kathy. So we'll talk more about those again as they enter and become closer to the marketplace. We'll take the next caller, please. Your next question comes from the line of Navin Jacob with UBS. Hi, thanks for taking the question. This is Saree Boroditsky on for Navin. I just want to get a little bit more granularity on the China Swine improvement. When exactly do you expect the China Swine market to normalize? And what do you expect the revenue impact to be on Elanco as China Swine prices start to normalize? And then a quick follow-up on inventory. Specifically, what was the inventory move for Bayer products in Q4? And are they back to normal levels at this point? And then on Elanco legacy products, was there any buildup of inventory in Q4? Thanks very much. Yeah, great questions. I'll start with China, and then Todd, you can maybe take the second one. But we would believe that the market will continue to have ASF challenges throughout the entire year. We see nothing that doesn't change that anticipation. Without question, and the government is supporting this with high pig prices and wanting to have domestic production and less dependency on imports, there is an acceleration to sophisticate the larger companies, the industrialized companies. Backyard farming, both in pigs and poultry, back even in the avian flu times, that's where it comes from. And it makes their supply chain and food chain much more vulnerable. So as an animal health industry, we fully support much more sophisticated biosecurity and larger companies that can afford these capabilities. So I see continued acceleration of an industrialized pig starting to match what is already in the poultry industry in the U.S. Transport of animals is another big factor coming from the smaller farms, and I see that to lessen over time as industrialized companies have more pigs. Ultimately, what I want you to hear is Elanco China will contribute one full percentage point of growth led by pigs, but also poultry and pets will also be a factor there. With respect to the Bayer side on U.S. pet, that's really retailers expanding the amount of product they're selling and thus holding more product in more stores online. While we thought that was about a $25 million kind of growth headwind in 2021 back in December, with the increase we saw of a $10 million pulled forward plus just continued growth in that, it's about a $35 million headwind from that aspect. And then the $10 million that we have taken out of our expectations for Q1, as that was just a timing between quarters. So overall, about an increase in the amount of inventory being held because of the increasing demand for the products and the dispensing that we've seen, it does create a growth headwind unless dispensing would grow faster in 2021 than what we currently expect right now. On the Elanco side, our inventory with distribution, so different than retailers, but with our distribution partners that serve vet clinics and farms, those inventory levels are consistent with the end of Q2 as well as consistent with the end of Q3 here at the end of Q4. Thanks. We'll end the call here, Operator. Thank you. And turning the call back over to management for closing remarks. Yes, thank you for the opportunity to share the results, and we look forward to engaging with all of you as we enter into 2021. Thank you. This concludes today's conference call. You may now disconnect.